Complex therapeutic molecules, proteins, and biologics demand an equally sophisticated approach to testing. For developers navigating regulatory milestones or preparing for a sale ahead of a Biologics License Application (BLA), knowing more about your molecule earlier can make all the difference.

The Eurofins BioPharma Product Testing (BPT) network of laboratories provides comprehensive, cGMP-compliant physico-chemical characterisation for large molecules, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion proteins, and biosimilars.

Our detailed analytical testing helps you gain a deeper understanding of the identity, structure, purity, and stability of your therapeutic candidates, supporting informed decisions at every stage of development.

By combining leading instrumentation with expert interpretation, our scientists deliver not just results, but insight that highlights the risks and potential formulation challenges that could impact downstream development or regulatory acceptance.

Demonstrating a well-characterised product can significantly enhance its appeal and valuation to potential partners or acquirers. Eurofins BPT is uniquely positioned to support smaller biotech companies who may seek to license or sell early-stage molecules.  

With access to advanced analytical platforms and proprietary methods, dedicated project management, and scalable support tailored to your molecule and development timeline, partner with Eurofins BPT to unravel the complexities of your large molecule therapies.